Background
Methods
Characterization of participants
Discovery cohort
| |||||
---|---|---|---|---|---|
Group
|
N
|
Gender (M:F)
| p
value
|
Age (mean ± SD)
| p
value
|
RIA | 10 | 8:2 | 52.4 ± 9.0 | ||
UIA | 10 | 8:2 | 55.2 ± 3.9 | ||
HC | 10 | 8:2 | 52.8 ± 6.9 | ||
DC | 10 | 8:2 | 1a | 54.6 ± 4.2 | 0.50b |
Validation cohort
| |||||
Group
|
N
|
M:F
|
p
value
|
Age
|
p
value
|
RIA | 20 | 7:13 | 51.7 ± 8.4 | ||
UIA | 20 | 7:13 | 51.2 ± 10.2 | ||
HC | 20 | 7:13 | 50.8 ± 7.6 | ||
DC | 20 | 7:13 | 1 a | 49.5 ± 7.7 | 0.85C |
Collection of CSF and plasma
Isolation of glycoproteins from CSF using lectin affinity column
iTRAQ labeling and two-dimensional liquid chromatography
Tandem MS analysis and protein identification and quantification
Functional annotation of identified proteins
Criteria for selecting candidate proteins for further validation
Validation of Soluble Axl (sAxl) in CSF and plasma by ELISA
Statistical analysis
Results
Identification of glycoproteins in human CSF
Changed glycoproteins in CSF associated with RIA and UIA
Protein name
|
iTRAQ ratios
a
| Nb | ||
---|---|---|---|---|
DC | RIA | UIA | ||
Proteins unique to RIA
| ||||
Immune/inflammatory response
| ||||
Complement C1s subcomponent precursor | 1.03 ± 0.10 |
1.28 ± 0.16
| 0.96 ± 0.11 | 4 |
Pigment epithelium-derived factor precursor | 1.29 ± 0.16 |
0.76 ± 0.05
| 1.22 ± 0.25 | 4 |
Cell Adhesion
| ||||
Alcadein alpha-1 | 1.22 ± 0.17 |
0.81 ± 0.03
| 1.32 ± 0.11 | 2 |
Calsyntenin-1 precursor | 0.78 ± 0.16 |
1.20 ± 0.12
| 0.82 ± 0.08 | 3 |
Contactin 2 precursor | 0.93 ± 0.14 |
1.20 ± 0.08
| 0.95 ± 0.21 | 5 |
Nectin-like protein 2 | 1.09 ± 0.15 |
0.61 ± 0.13
| 1.62 ± 0.23 | 3 |
Neural cell adhesion molecule 1, 140 kDa isoform precursor | 0.88 ± 0.12 |
0.44 ± 0.14
| 0.97 ± 0.21 | 3 |
Extracellular Matrix
| ||||
Secretogranin III precursor | 0.83 ± 0.05 |
0.63 ± 0.04
| 1.00 ± 0.16 | 3 |
Splice isoform 1 of fibrinogen gamma chain precursor | 0.96 ± 0.15 |
1.52 ± 0.19
| 1.18 ± 0.12 | 3 |
Splice isoform 1 of fibulin-1 precursor | 1.03 ± 0.12 |
0.64 ± 0.11
| 1.09 ± 0.15 | 3 |
Protein synthesis or protein degradation
| ||||
Hypothetical protein FLJ23322 | 0.64 ± 0.09 |
1.43 ± 0.14
| 0.46 ± 0.05 | 2 |
Hypothetical protein FLJ23757 | 1.07 ± 0.08 |
3.79 ± 0.53
| 0.99 ± 0.10 | 2 |
PREDICTED: KIAA1509 | 0.64 ± 0.18 |
1.43 ± 0.11
| 0.46 ± 0.27 | 2 |
Splice isoform 1 of ecto-ADP-ribosyltransferase 3 precursor | 1.20 ± 0.16 |
3.05 ± 0.31
| 1.15 ± 0.23 | 2 |
TAR RNA loop binding protein | 0.71 ± 0.25 |
1.50 ± 0.16
| 1.14 ± 0.08 | 3 |
Transport
| ||||
Afamin precursor | 1.18 ± 0.08 |
1.39 ± 0.05
| 1.19 ± 0.12 | 4 |
Ceruloplasmin precursor | 1.28 ± 0.14 |
0.76 ± 0.19
| 0.94 ± 0.19 | 10 |
Neuronal pentraxin I precursor | 1.07 ± 0.10 |
0.67 ± 0.04
| 0.88 ± 0.03 | 2 |
Serotransferrin precursor | 0.98 ± 0.47 |
0.76 ± 0.50
| 0.96 ± 0.35 | 59 |
Apoptosis or anti-apoptosis
| ||||
AXL receptor tyrosine kinase, isoform 1
| 1.12 ± 0.11 |
1.68 ± 0.07
| 0.87 ± 0.16 | 2 |
Splice isoform 1 of amine oxidase flavin containing domain protein 2 | 0.88 ± 0.13 |
0.38 ± 0.14
| 1.12 ± 0.08 | 2 |
Beta-2-glycoprotein I precursor | 0.85 ± 0.14 |
1.48 ± 0.20
| 1.09 ± 0.09 | 4 |
Ephrin A1 isoform b precursor | 0.75 ± 0.06 |
1.23 ± 0.03
| 1.18 ± 0.02 | 2 |
Tyrosine phosphatase zeta polypeptide 2 HTPZP2 | 1.32 ± 0.21 |
0.43 ± 0.12
| 1.20 ± 0.19 | 2 |
Cell proliferation/differentiation/migration
| ||||
Splice isoform 1 of erythrocyte membrane protein band 4.2 | 0.93 ± 0.09 |
3.86 ± 0.49
| 1.53 ± 0.11 | 2 |
Signal transduction
| ||||
XPR1 protein | 0.88 ± 0.18 |
0.38 ± 0.07
| 1.12 ± 0.15 | 2 |
Metabolism
| ||||
Guanylate binding protein 4 | 1.26 ± 0.13 |
0.68 ± 0.10
| 1.07 ± 0.11 | 2 |
Splice isoform 2 of adenosine kinase | 0.88 ± 0.08 |
0.38 ± 0.15
| 1.12 ± 0.11 | 2 |
Splice isoform 2 of phospholipid transfer protein precursor | 0.71 ± 0.23 |
1.45 ± 0.07
| 0.86 ± 0.16 | 2 |
Cell structure/cytoskeleton
| ||||
Nebulin | 1.11 ± 0.21 |
1.74 ± 0.30
| 1.18 ± 0.09 | 3 |
PREDICTED: dynein, cytoplasmic, heavy polypeptide 2 | 0.88 ± 0.09 |
0.38 ± 0.12
| 1.12 ± 0.16 | 2 |
Splice isoform 3 o myosin Va | 0.68 ± 0.29 |
1.55 ± 0.15
| 1.14 ± 0.08 | 3 |
Titin | 1.08 ± 0.14 |
0.64 ± 0.07
| 1.07 ± 0.13 | 2 |
Unknown
| ||||
17-beta hydroxysteroid dehydrogenase | 0.80 ± 0.21 |
1.75 ± 0.23
| 1.12 ± 0.16 | 2 |
Chromosome 1 open reading frame 27 | 0.88 ± 0.17 |
0.38 ± 0.12
| 1.12 ± 0.16 | 2 |
JRK protein | 1.05 ± 0.05 |
1.77 ± 0.17
| 0.69 ± 0.06 | 2 |
PREDICTED: KIAA1522 protein | 0.60 ± 0.16 |
1.40 ± 0.20
| 0.84 ± 0.12 | 2 |
PREDICTED: similar to RIKEN cDNA 1700022C21 | 0.80 ± 0.21 |
1.75 ± 0.16
| 1.12 ± 0.10 | 2 |
Taste receptor type 2 member 7 | 0.88 ± 0.12 |
0.38 ± 0.06
| 1.12 ± 0.04 | 2 |
Zinc finger MYND domain containing protein 19 | 0.97 ± 0.03 |
1.31 ± 0.12
| 0.86 ± 0.08 | 2 |
Proteins unique to UIA
| ||||
Immune/inflammatory response
| ||||
Complement C5 precursor | 1.34 ± 0.15 | 1.09 ± 0.07 |
0.68 ± 0.05
| 2 |
Cell Adhesion
| ||||
Splice isoform 1 of neogenin precursor | 1.05 ± 0.10 | 1.10 ± 0.14 |
0.71 ± 0.12
| 3 |
Protein synthesis or protein degradation
| ||||
Hypothetical protein FLJ34458 | 1.13 ± 0.10 | 0.94 ± 0.12 |
0.63 ± 0.03
| 2 |
SERPIND1 protein | 1.01 ± 0.15 | 1.00 ± 0.08 |
1.21 ± 0.06
| 4 |
Transport
| ||||
Transthyretin precursor | 0.95 ± 0.15 | 0.88 ± 0.07 |
0.69 ± 0.11
| 5 |
Apoptosis or anti-apoptosis
| ||||
Baculoviral IAP repeat-containing protein 4 | 1.20 ± 0.11 | 1.00 ± 0.06 |
0.47 ± 0.08
| 2 |
Nectin-like protein 2 | 1.09 ± 0.15 | 0.61 ± 0.13 |
1.62 ± 0.23
| 3 |
Nucleolysin TIAR | 0.93 ± 0.07 | 0.88 ± 0.12 |
0.68 ± 0.06
| 3 |
Splice isoform 2 of signal transducer and activator of transcription 1-alpha/beta | 1.13 ± 0.06 | 0.94 ± 0.03 |
0.63 ± 0.10
| 2 |
Cell proliferation/differentiation/migration
| ||||
Condensin subunit 2 | 0.85 ± 0.10 | 0.87 ± 0.09 |
0.55 ± 0.08
| 3 |
Signal transduction
| ||||
Grb10 interacting GYF protein 1 | 1.13 ± 0.05 | 0.94 ± 0.14 |
0.63 ± 0.02
| 2 |
Metabolism
| ||||
Vitamin D-binding protein precursor | 1.14 ± 0.10 | 1.06 ± 0.18 |
1.29 ± 0.09
| 6 |
Unknown
| ||||
JRK protein | 1.05 ± 0.05 | 1.77 ± 0.17 |
0.69 ± 0.06
| 2 |
Proteins changed both in RIA and UIA
| ||||
Immune/inflammatory response
| ||||
Complement C3 precursor | 0.91 ± 0.40 |
1.28 ± 0.42
|
1.25 ± 0.33
| 16 |
Splice isoform 2 of interleukin-17E precursor | 1.21 ± 0.09 |
0.62 ± 0.13
|
0.67 ± 0.12
| 2 |
Cell Adhesion
| ||||
Neurocan core protein precursor | 0.91 ± 0.15 |
0.44 ± 0.10
|
0.54 ± 0.12
| 3 |
Splice isoform 2 of fibrinogen alpha/alpha-E chain precursor | 1.14 ± 0.16 |
0.56 ± 0.12
|
0.78 ± 0.13
| 4 |
Extracellular Matrix
| ||||
Extracellular matrix protein 1 | 1.16 ± 0.12 |
0.55 ± 0.15
|
0.69 ± 0.13
| 3 |
Metalloproteinase inhibitor 1 precursor | 1.07 ± 0.11 |
1.25 ± 0.08
|
1.31 ± 0.12
| 4 |
Protein synthesis or protein degradation
| ||||
Acheron, isoform 1 | 0.97 ± 0.03 |
1.31 ± 0.08
|
1.64 ± 0.16
| 2 |
Transport
| ||||
Apolipoprotein D precursor | 1.19 ± 0.08 |
1.43 ± 0.12
|
1.47 ± 0.11
| 3 |
Serum albumin precursor | 1.08 ± 0.17 |
1.39 ± 0.11
|
1.59 ± 0.12
| 4 |
Cell proliferation/differentiation/migration
| ||||
Septin 10 isoform 2 | 1.08 ± 0.02 |
1.28 ± 0.05
|
1.46 ± 0.08
| 2 |
Signal transduction
| ||||
Adrenomedullin 2 precursor | 1.08 ± 0.04 |
1.30 ± 0.07
|
1.28 ± 0.04
| 2 |
CD59 glycoprotein precursor | 0.90 ± 0.07 |
0.49 ± 0.03
|
0.64 ± 0.06
| 2 |
Neuronal pentraxin receptor isoform 1 | 1.00 ± 0.02 |
0.74 ± 0.05
|
0.50 ± 0.11
| 3 |
Metabolism
| ||||
Lumican precursor | 0.99 ± 0.13 |
1.57 ± 0.04
|
1.36 ± 0.13
| 3 |
N-acetylgalactosamine-4-O-sulfotransferase | 0.88 ± 0.05 |
1.21 ± 0.08
|
1.28 ± 0.07
| 2 |
Cell structure/cytoskeleton
| ||||
Keratin 1 | 1.49 ± 0.17 |
0.66 ± 0.07
|
0.82 ± 0.07
| 3 |
PREDICTED: similar to keratin, type I cytoskeletal 18 (cytokeratin 18) (K18) (CK 18) | 1.73 ± 0.28 |
0.69 ± 0.06
|
0.76 ± 0.08
| 2 |
Unknown
| ||||
DJ570F3.6 | 0.69 ± 0.23 |
2.36 ± 0.36
|
2.14 ± 0.24
| 2 |
MUF1 protein | 1.09 ± 0.08 |
0.72 ± 0.10
|
0.72 ± 0.11
| 3 |
PREDICTED: hypothetical protein XP_291007
| 0.97 ± 0.06 |
0.59 ± 0.04
|
0.60 ± 0.04
| 2 |
Validation of sAxl as a potential marker for IA rupture
Group
|
iTRAQ ratio (mean ± SD)
|
ELISA ratio
a
(mean ± SD)
|
ELISA concentration (nM) (mean ± SD)
|
---|---|---|---|
RIA | 1.68 ± 0.07 | 2.35 ± 0.24*, #, $ | 0.204 ± 0.017 *, #, $ |
UIA | 0.87 ± 0.16 | 0.98 ± 0.47 | 0.082 ± 0.030 |
DC | 1.12 ± 0.11 | 1.52 ± 0.48 | 0.128 ± 0.022 |
HC | - | - | 0.088 ± 0.017 |
sAxl in CSF (n = 30/group)
| ||||
---|---|---|---|---|
Cut off (nM)
|
Sensitivity % (95% CI)
|
Specificity % (95% CI)
|
LR+
|
LR-
|
0.02 | 100.00 (88.43 to 100.00) | 13.33 (3.76 to 30.72) | 1.15 | 0.00 |
0.09 | 90.00 (73.47 to 97.89) | 66.67 (47.19 to 82.71) | 2.70 | 0.15 |
0.10 | 86.67 (69.28 to 96.24) | 70.00 (50.60 to 85.27) | 2.89 | 0.19 |
0.11 | 76.67 (57.72 to 90.07) | 83.33 (65.28 to 94.36) | 4.60 | 0.28 |
0.12 | 73.33 (54.11 to 87.72) | 90.00 (54.11 to 87.72) | 7.33 | 0.30 |
0.14 | 63.33 (43.86 to 80.07) | 93.33 (77.93 to 99.18) | 9.50 | 0.39 |
sAxl in plasma (n = 20/group)
| ||||
Cut off (nM)
|
Sensitivity % (95% CI)
|
Specificity % (95% CI)
|
LR+
|
LR-
|
0.4 | 100 (83.16 to 100.0) | 5 (0.1265 to 24.87) | 1.05 | 0.00 |
0.5 | 90 (68.30 to 98.77) | 15 (3.207 to 37.89) | 1.06 | 0.67 |
1 | 80 (56.34 to 94.27) | 45 (23.06 to 68.47) | 1.45 | 0.44 |
1.2 | 65 (40.78 to 84.61) | 65 (40.78 to 84.61) | 1.86 | 0.54 |
1.7 | 50 (27.20 to 72.80) | 80 (56.34 to 94.27) | 2.50 | 0.63 |